Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

By Revicki Dennis   Willian Mary Kaye   Menter Alan   Gordon Kenneth   Kimball Alexa   Leonardi Craig   Langley Richard   Kimel Miriam   Okun Martin  

Journal of Dermatological Treatment, Vol. 18, Iss. 6, 2007-01 ,pp. : 341-350

Informa Healthcare

Access to resources Recommend Favorite

Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States

By Anis Aslam H.   Bansback Nick   Sizto Sonia   Gupta Shiraz R.   Willian Mary K.   Feldman Steve R.  

Journal of Dermatological Treatment, Vol. 22, Iss. 2, 2011-04 ,pp. : 65-74

Informa Healthcare

Access to resources Recommend Favorite

Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II

By Papp Kim   Camisa Charles   Stone Stephen   Caro Ivor   Wang Xiaolin   Compton Peter   Walicke Patricia   Gottlieb Alice  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 313-323

Springer Publishing Company

Access to resources Recommend Favorite

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

By Martin Silas   Feldman Steven R.   Augustin Matthias   Szapary Philippe   Schenkel Brad  

Journal of Dermatological Treatment, Vol. 22, Iss. 3, 2011-06 ,pp. : 138-143

Informa Healthcare

Access to resources Recommend Favorite

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

By Papp Kim   Ho Vincent   Langley Richard   Lynde Charles   Poulin Yves   Shear Neil   Toole John   Zip Catherine  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 26-32

Springer Publishing Company

Access to resources Recommend Favorite